Tislelizumab plus chemotherapy for advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This study tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy (SOX) as a first treatment for locally advanced stomach or gastroesophageal junction cancer. It aims to see if this combination can help shrink the tumor before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- Your cancer is HER2-negative (a certain protein level is low).
- Your tumor has a PD-L1 level of 1 or higher (a marker that may help immunotherapy work).
- You have not had any previous chemotherapy, targeted therapy, or surgery for this type of cancer.
- You do not have an active autoimmune disease that requires treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding immunotherapy to standard chemotherapy after surgery can help prevent stomach or gastroesophageal junction cancer from coming back. It is for people whose cancer has been fully removed and who need further treatment.
This trial tests whether adding an immunotherapy drug (tislelizumab) to standard chemotherapy before and after surgery can help treat stomach or gastroesophageal junction cancer. It is for people whose cancer has not spread to other organs and who are well enough to have surgery.
This trial tests whether adding a drug called tislelizumab (an immunotherapy) to standard chemotherapy before and after surgery is better than chemotherapy alone for people with a specific type of stomach or GEJ cancer that has a high level of a marker called MHC class II. The goal is to see if it helps shrink the tumor and improves the chance of successful surgery.
This trial tests a combination of an immunotherapy drug (tislelizumab) and chemotherapy after surgery to prevent stomach cancer from coming back in older patients. It may be a good option for people who have had their cancer completely removed and are in good overall health.
This study tests a treatment approach for stomach cancer that hasn't spread to other organs. It's for people who have not had any prior cancer treatments and are in relatively good health.
This trial tests a new combination of treatments for stomach cancer that has spread to the lining of the abdomen. It uses an immunotherapy drug (tislelizumab) with chemotherapy (SOX) and heated chemotherapy directly into the abdomen (HIPEC) to see if it works better than standard care.
Hear when a new Gastric / Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.